Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle